Biomarin Pharmaceutical (BMRN) Goodwill & Intangibles (2009 - 2026)

Biomarin Pharmaceutical (BMRN) has 18 years of Goodwill & Intangibles data on file, last reported at $400.9 million in Q1 2026.

• Quarterly Goodwill & Intangibles fell 9.62% year-over-year to $400.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $400.9 million (down 9.62% YoY) and the FY2025 annual result came in at $410.0 million, down 9.18% from the prior year.
• Goodwill & Intangibles retreated to $400.9 million in Q1 2026, from $410.0 million in the prior quarter.
• In the past five years, Goodwill & Intangibles ranged from a high of $570.4 million in Q1 2022 to a low of $400.9 million in Q1 2026.
• A 5-year average of $482.7 million and a median of $475.9 million in 2024 frame the typical range for Goodwill & Intangibles.
• Annual changes were most pronounced in 2022 — Goodwill & Intangibles fell 4.22% — and 2023, when it fell 10.44%.
• Tracing BMRN's Goodwill & Intangibles over 5 years: stood at $534.8 million in 2022, then slipped by 8.2% to $490.9 million in 2023, then fell by 8.03% to $451.5 million in 2024, then slipped by 9.18% to $410.0 million in 2025, then slipped by 2.24% to $400.9 million in 2026.
• The last three Goodwill & Intangibles figures came in at $400.9 million (Q1 2026), $410.0 million (Q4 2025), and $429.3 million (Q3 2025), per Business Quant data.